Skip to main content
Premium Trial:

Request an Annual Quote

Silicon Kinetics to Participate in Japanese Clinical Proteomics Project

NEW YORK (GenomeWeb) – Biosensor firm Silicon Kinetics said today it is collaborating with Biosys Technologies, Tokyo University, and St. Marianna University School of Medicine in Japan on a screening project for lung cancer drugs.

Under the terms of the collaboration, the parties will use Silicon Kinetics' Molecular Interaction Kinetics-Mass Spectrometry (MIK-MS) technology to screen and rank inhibitors targeting lung cancer as part of a larger study investigating the progression of lung cancer in non-smoking adults, along with potential personalized treatments.

The MIK-MS system allows researchers to capture and assess the kinetics of candidate inhibitors on silicon biosensors and then pass on these inhibitors to an inline mass spec system for identification and quantification.

The approach "forms the basis for state-of-the art-screening, as it not only enables novel protein identification but also gives information about protein interactions, signal pathways and mutations in conjunction with databases and related informatics," Toshihide Nishimura, director of translational medicine informatics and St. Marianna University School of Medicine, said in a statement.

Further terms of the collaboration were not disclosed.